title: Hormonal control of spermatogenesis in men: therapeutic aspects in hypogonadotropic hypogonadism.
abstract: During the first two trimesters of intrauterine life, fetal sex steroid production is driven by maternal human chorionic gonadotropin (hCG). The HPG axis is activated around the third trimester and remains active for the first 6-months of neonatal life. This so-called mini-puberty is a developmental window that has profound effects on future potential for fertility. In early puberty, GnRH secretion is reactivated first at night and then night and day. Pulsatile GnRH stimulates both LH and FSH, which induce maturation of the seminiferous tubules and Leydig cells. Congenital hypogonadotropic hypogonadism (CHH) results from GnRH deficiency. Men with CHH lack the mini-pubertal and pubertal periods of Sertoli Cell proliferation and thus present with prepubertal testes (<4mL) and low inhibin serum levels --reflecting diminished SC numbers. To induce full maturation of the testes, GnRH-deficient patients can be treated with either pulsatile GnRH, hCG or combined gonadotropin therapy (FSH+hCG). Fertility outcomes with each of these regimens are highly variable. Recently, a randomized, open label treatment study (n=13) addressed the question of whether a sequential treatment with FSH alone prior to LH and FSH (via GnRH pump) could enhance fertility outcomes. All men receiving the sequential treatment developed sperm in the ejaculate, whereas 2/6 men in the other group remained azoospermic. A large, multicenter clinical trial is needed to definitively prove the optimal treatment approach for severe CHH.
authors.affiliation: Endocrine, diabetes, & metabolism service, centre hospitalier universitaire Vaudois, rue du Bugnon-46, 1011 Lausanne, Switzerland. Electronic address: nelly.pitteloud@chuv.ch.
authors.forename: Nelly
authors.initials: N
authors.lastname: Pitteloud
authors.affiliation: Endocrine, diabetes, & metabolism service, centre hospitalier universitaire Vaudois, rue du Bugnon-46, 1011 Lausanne, Switzerland.
authors.forename: Andrew
authors.initials: A
authors.lastname: Dwyer
mesh_terms: D000293:Adolescent; D053713:Azoospermia / Q000188:drug therapy / Q000209:etiology; D002648:Child; D006063:Chorionic Gonadotropin / Q000502:physiology / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000502:physiology / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000172:deficiency / Q000502:physiology / Q000627:therapeutic use; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy / Q000503:physiopathology*; D007223:Infant; D007231:Infant, Newborn; D007248:Infertility, Male / Q000188:drug therapy / Q000209:etiology; D007986:Luteinizing Hormone / Q000502:physiology; D008297:Male; D013091:Spermatogenesis / Q000502:physiology*; D013737:Testis / Q000254:growth & development / Q000503:physiopathology; D013739:Testosterone / Q000502:physiology
chemical_list: D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
keywords: FSH sequential treatment; Hypogonadisme hypogonadotrope; Hypogonadotropic hypogonadism; Mini-puberty; Minipuberté; Spermatogenesis; Spermatogenèse; Traitement séquentiel par la FSH